2024-10-23 Hesai Technology HaiPress
PALO ALTO,Calif.,Oct. 22,2024 -- Hesai Technology (NASDAQ: HSAI),the global leader in lidar solutions,announced this week that it will be the exclusive provider of automotive long-range lidar for Leapmotor's next-generation vehicle platform. The platform's first model is expected to enter mass production in 2025.
According to the agreement,Hesai Technology will provide lidar products for multiple models of Leapmotor's next-generation new vehicle platform. This exclusive partnership deepens their long-term collaboration in intelligent driving,highlighting Hesai's leading lidar technology and Leapmotor's continued trust in Hesai and its capabilities.
In line with the initial strategic partnership established earlier this year,the two companies have advanced intelligent driving projects for multiple new Leapmotor models. The popular Leapmotor C-series intelligent driving edition models are fully equipped with Hesai's ultra-high-definition long-range AT128 lidar,enabling Navigation Assist Pilot (NAP),Navigation Assisted Cruise (NAC) and other advanced intelligent driving functions. According toLeapmotor,as of September 23rd,it has already commenced sales in Europe,with over 200 dealers across 13 countries. The company plans to expand this footprint to 500 sales points in Europe by the end of 2025.
Hesai Technology will continue to deepen its exclusive partnership with Leapmotor,leveraging each company's respective strengths in advanced driver-assistance systems (ADAS). In the future,the two companies will continue to cooperate closely on intelligent driving,helping Leapmotor accelerate its leadership in ADAS and the technology's application globally.
SILVERSEA UNVEILS NEW BRAND POSITIONING, HONORING GUESTS' ENDURING COMMITMENT 'TO FINDING MORE'
$1 Billion Financing Secured, Visionary Accelerates Its Battery Swap Layout in Hong Kong
"Cloud-borne School Bus": Once a Daunting Journey, Now an Accessible Route to Education
Embracing the AI Era: Huawei Cloud Thailand Launched New Cloud Service Series to Accelerate Enterprises' Shift to AI-Native
Florbetaben (18F) Injection (Neuraceq®) Set to Launch at St. Teresa's Hospital in Hong Kong in March 2025
NYSE Content advisory: Pre-market update for March 14, 2025
©copyright2009-2020Fresh life